Ehud Zeltzer

Ehud Zeltzer

Auto-generated profile, based on publicly available information

Ehud Zeltzer

Department of Neurology University of California, San Francisco San Francisco CA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2014 in Foot & Ankle International
Verified
Journal Article
Closed access
YMYael Milgrom
Yael Milgrom
CMCharles Milgrom
Charles Milgrom
TATalya Altaras
Talya Altaras
OGOpher Globus
Opher Globus
EZEhud Zeltzer
Ehud Zeltzer
AFAharon S Finestone
Aharon S Finestone
Background: Whether the human Achilles tendon undergoes hypertrophic changes as measured by an increase in cross-sectional area, in response to endurance training exercise remains in question. We investigated the hypothesis that transition from civilian life through 6 months of elite infantry training would induce adaptive Achilles tendon hypertrophy. Methods: Seventy-two new elite infantry recruits had the cross-sectional area of their Achilles tendons measured at a point 2.5 cm proximal to the Achilles insertion by ultrasound before beginning elite infantry training. Measurements were repeated by the same ultrasonographer for those recruits who were still in the training program at 6 months. Prior to beginning the study the intraobserver reliability of the ultrasonographer’s Achilles tendon measurements was calculated (intraclass correlation coefficient = .96). Fifty-five recruits completed 6 months of training. Results: The mean cross-sectional area of their right Achilles tendon increased from 47.0 ± 11.2 to 50.2 ± 9.6 mm2 ( P = .037) and the left Achilles tendon from 47.2 ± 8.9 to 51.1 ± 8.3 mm2 ( P = .013). The change in cross-sectional area did not correlate with subject height, weight, prior sport history, or jumping and running abilities. Conclusions: An abrupt stimulus of 6 months of elite infantry training was adequate to induce hypertrophic changes in the Achilles tendon. This is the first human prospective study showing an increase in the Achilles tendon cross-sectional area in response to rigorous endurance type training. The finding supports the hypothesis that the Achilles tendon in response to sufficiently high and sustained loading can remodel its morphological properties and thereby strengthen itself. Level of Evidence: Level II, etiology study.

17 March 2025 in Annals of Neurology
Verified
Journal Article
Closed access
JLJulien Lagarde
Julien Lagarde
PMPiyush Maiti
Piyush Maiti
DSDaniel R. Schonhaut
Daniel R. Schonhaut
GBGanna Blazhenets
Ganna Blazhenets
JZJiaxiuxiu Zhang
Jiaxiuxiu Zhang
TIthe LEADS Consortium for the Alzheimer's Disease Neuroimaging Initiative
the LEADS Consortium for the Alzheimer's Disease Neuroimaging Initiative

27 May 2022 in European Stroke Journal
Verified
Journal Article
Open access
EAEinor Ben Assayag
Einor Ben Assayag
JMJeremy Molad
Jeremy Molad
ESEstelle Seyman
Estelle Seyman
OROfer Rotschild
Ofer Rotschild
EZEhud Zeltzer
Ehud Zeltzer
HHHen Hallevi
Hen Hallevi
: Background: Current evidence suggest that 25%–33% of stroke-survivors develop post-stroke cognitive impairment (PSCI). The licensed drug Maraviroc, a CCR5-antagonist, is postulated to act via a neuroprotective mechanism that may offer the potential of preventing progression to vascular dementia. Our hypothesis: Maraviroc may have the potential to augment learning skills and cognitive performance by affecting synaptic plasticity, along with neuro-inflammatory modulation in patients with cerebral small vessel disease (SVD) and PSCI. Design: MARCH is a multi-center, double-blind randomized-control Phase-II trial of Maraviroc 150 or 600 mg/day versus placebo for 12-months in five stroke centers in Israel. Included are patients diagnosed with recent (1–24 months) subcortical stroke who experience mild PSCI and have evidence of white matter lesions and SVD on neuroimaging. Outcomes: Primary outcomes: 1. Change in cognitive scores. 2. Drug related adverse events. Secondary outcomes: change in functional and affective scores, MRI-derived measures, inflammatory markers, carotid atherosclerosis, cerebrospinal-fluid biomarkers in a sub-study. A sample size of 60 in each treatment group and 30 in the placebo group (total – 150 participants) provides 80% power between the treatment and the placebo groups. Conclusions: The results of this work could lead to a novel, readily available, therapeutic avenue to reduce PSCI, and possibly other pathologies. This study will test safety and effectiveness of Maraviroc in limiting cognitive deterioration and/or post stroke cognitive impairment in patients with cerebral small vessel disease. Schedule: First-patient first-visit was May 2021. Recruitment to complete in 2023, follow-up to complete in 2024.

4 November 2024 in medRxiv
Verified
Preprint
Open access
PDF file
EZEhud Zeltzer
Ehud Zeltzer
DSDaniel R. Schonhaut
Daniel R. Schonhaut
NMNidhi S. Mundada
Nidhi S. Mundada
GBGanna Blazhenets
Ganna Blazhenets
JPJhony Mejia Perez
Jhony Mejia Perez
RJRenaud La Joie
Renaud La Joie
Amyloid-PET detects fibrillar β-amyloid deposits, a defining feature of Alzheimer’s disease. This technology has been used in research for over 20 years, and is now used in clinical practice to guide patient diagnosis and management. However, the real-world use of amyloid-PET may differ from research settings due to less standardized acquisition protocols, less experienced visual readers, and patients with more comorbidities, potentially compromising test accuracy. We evaluated the performance of amyloid-PET as used in a real-world clinical setting utilizing data collected via the Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) study. The study collected clinical amyloid-PET scans of older adults with cognitive decline acquired in 294 imaging facilities using three FDA-approved radiotracers. We centrally processed these scans using a PET-only processing pipeline and derived summary quantification of cerebral radiotracer retention measured on the Centiloid scale. We applied an a priori autopsy-based threshold of 24.4 Centiloids to quantitatively define scan positivity and compared this quantitative classification with binary visual reads performed by local radiologists or nuclear medicine physicians. 10,350/10,774 scans (96%) passed quality control and were successfully quantified. Median patient age was 75 (interquartile range 71, 80) years, 51% were females, 87% self-identified as White, 63% had mild cognitive impairment (vs. 37% with dementia), and 61% of scans were visually positive based on local reads. Centiloid values were higher in visually positive scans (median=74 [46, 99]) compared to scans locally read as negative (−2 [−13, 12]; p<0.001). Patients with dementia had higher Centiloids than those with mild cognitive impairment (57 [8, 91] vs. 34 [−2, 79]; p<0.001), consistent with a higher visual positivity rate (70% vs. 56%, respectively; p<0.001). Agreement between local visual reads and quantitative classification was 86.3% (95%CI: 85.7%, 87.0%), corresponding to Cohen’s Kappa of 0.715 (95%CI: 0.701, 0.729; p<0.001). Overall, 5,519 [53% of total] scans were positive by both visual read and quantification (V+/Q+); 3,416 [33%] were negative by both (V-/Q-), 813 [8%] were V+/Q-, and 602 [6%] were V-/Q+. Female sex, White race, and use of the radiotracers 18 F-flutemetamol and 18 F-florbetaben (compared to 18 F-florbetapir) were associated with higher visual-quantitative concordance. In conclusion, local visual reads showed high concordance with central quantification of clinical amyloid-PET scans, supporting the validity of amyloid-PET as used in the real world and the use of quantification in clinical settings.